Your session is about to expire
← Back to Search
Group Education for Cancer Screening
N/A
Waitlist Available
Led By Jose Rauh-Hain, MD,MPH
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Arm 1: Diagnosis of MDS intermediate/high/very high risk by Revised International Prognostic Scoring System (IPSS-R), Untreated or up to 2 prior treatments
Arm 2: Diagnosis of relapsed/refractory AML (per European Leukemia Network 2022) receiving treatment as salvage 1-2
Must not have
Patients with any other known concurrent severe and/or uncontrolled medical condition
Prior organ transplantation within 3 months prior to planned enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if group education sessions can help medically underserved women and minorities with BRCA 1 and 2 mutations to better follow recommended screening and risk-reducing procedures.
Who is the study for?
This trial is for medically underserved women and racial/ethnic minorities who have BRCA 1 or 2 gene mutations, which are linked to a higher risk of cancer. Participants should be interested in learning about surveillance and procedures to reduce their cancer risk.
What is being tested?
The study is testing an educational program delivered through group sessions. The goal is to see if this intervention can help participants follow recommended health screenings and preventive measures more closely.
What are the potential side effects?
Since the interventions involve education content and focus groups, there aren't any direct medical side effects. However, discussing sensitive topics like cancer risks may cause emotional or psychological discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My MDS is intermediate/high/very high risk and I've had 0-2 treatments.
Select...
I have AML that has come back or didn't respond to treatment, and I'm on my first or second attempt at salvage therapy.
Select...
I am 18 years old or older.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am following the required birth control measures or am unable to have children.
Select...
I am a male following the required guidelines for contraception or am sterile.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any severe or uncontrolled medical conditions.
Select...
I had an organ transplant less than 3 months ago.
Select...
My leukemia affects my brain and is not well-managed.
Select...
My condition is currently active and not under control.
Select...
I am currently receiving cancer treatment for another cancer.
Select...
I have HIV that is not currently under control.
Select...
I have not had major surgery in the last 14 days.
Select...
I do not have any severe or poorly controlled health conditions.
Select...
I need to take anti-TNF drugs.
Select...
I have not received a live vaccine in the last 28 days.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion; an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and Adverse Events (AEs)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Standard of CareExperimental Treatment1 Intervention
Participants will be randomized into one of two arms through REDCap
Group II: ACT-Together InterventionExperimental Treatment1 Intervention
Participants will be randomized into one of two arms through REDCap
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,071 Previous Clinical Trials
1,803,188 Total Patients Enrolled
Jose Rauh-Hain, MD,MPHPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
247 Total Patients Enrolled